A clinical trial update was recorded on September 22, 2026, for mazdutide, listed under the identifier IBI362. The study, titled "A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity," is registered as NCT06862908. This is a Phase 2 trial. Its current status is active, not recruiting, meaning participant enrollment has concluded but the study is ongoing.
The trial is designed to evaluate mazdutide in subjects who have heart failure with preserved ejection fraction (HFpEF) or heart failure with mildly reduced ejection fraction (HFmrEF), combined with obesity. No results have been posted for this trial as of this update, and no efficacy or safety outcomes are described in the available record.
Mazdutide remains classified as an unapproved compound under research status. This update reflects only the trial's registered status and design as of the date listed. Further information, including outcomes, would be expected as the trial progresses and if results are subsequently posted to the registry.
Readers interested in additional background can consult the compound overview for more context on mazdutide.